Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Supplemental material
  • Version history
  • Article usage
  • Citations to this article
Advertisement

ResearchIn-Press PreviewClinical ResearchImmunologyInfectious disease Open Access | 10.1172/jci.insight.201111

Pediatric long COVID is characterized by myeloid CCR6 suppression and immune dysregulation

Jon Izquierdo-Pujol,1 Núria Pedreño-Lopez,1 Tetyana Pidkova,1 Maria Nevot,1 Victor Urrea,1 Fernando Laguía,1 Francisco Muñoz-López,1 Judith Dalmau,1 Alba Gonzalez-Aumatell,2 Clara Carreras-Abad,2 María Méndez,2 Carlos Rodrigo,2 Marta Massanella,1 Julià Blanco,1 Jorge Carrillo,1 Benjamin Trinité,1 Javier Martinez-Picado,1 and Sara Morón-López1

1IrsiCaixa, Badalona, Spain

2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain

Find articles by Izquierdo-Pujol, J. in: PubMed | Google Scholar

1IrsiCaixa, Badalona, Spain

2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain

Find articles by Pedreño-Lopez, N. in: PubMed | Google Scholar

1IrsiCaixa, Badalona, Spain

2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain

Find articles by Pidkova, T. in: PubMed | Google Scholar

1IrsiCaixa, Badalona, Spain

2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain

Find articles by Nevot, M. in: PubMed | Google Scholar

1IrsiCaixa, Badalona, Spain

2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain

Find articles by Urrea, V. in: PubMed | Google Scholar

1IrsiCaixa, Badalona, Spain

2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain

Find articles by Laguía, F. in: PubMed | Google Scholar

1IrsiCaixa, Badalona, Spain

2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain

Find articles by Muñoz-López, F. in: PubMed | Google Scholar

1IrsiCaixa, Badalona, Spain

2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain

Find articles by Dalmau, J. in: PubMed | Google Scholar

1IrsiCaixa, Badalona, Spain

2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain

Find articles by Gonzalez-Aumatell, A. in: PubMed | Google Scholar

1IrsiCaixa, Badalona, Spain

2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain

Find articles by Carreras-Abad, C. in: PubMed | Google Scholar

1IrsiCaixa, Badalona, Spain

2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain

Find articles by Méndez, M. in: PubMed | Google Scholar

1IrsiCaixa, Badalona, Spain

2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain

Find articles by Rodrigo, C. in: PubMed | Google Scholar

1IrsiCaixa, Badalona, Spain

2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain

Find articles by Massanella, M. in: PubMed | Google Scholar |

1IrsiCaixa, Badalona, Spain

2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain

Find articles by Blanco, J. in: PubMed | Google Scholar |

1IrsiCaixa, Badalona, Spain

2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain

Find articles by Carrillo, J. in: PubMed | Google Scholar |

1IrsiCaixa, Badalona, Spain

2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain

Find articles by Trinité, B. in: PubMed | Google Scholar

1IrsiCaixa, Badalona, Spain

2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain

Find articles by Martinez-Picado, J. in: PubMed | Google Scholar |

1IrsiCaixa, Badalona, Spain

2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain

Find articles by Morón-López, S. in: PubMed | Google Scholar |

Published February 19, 2026 - More info

JCI Insight. https://doi.org/10.1172/jci.insight.201111.
Copyright © 2026, Izquierdo-Pujol et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published February 19, 2026 - Version history
View PDF
Abstract

The biological mechanisms underlying long COVID in the pediatric population are poorly understood. Our study aimed to characterize the immune pathophysiology of long COVID in children and young people (CYP). We analyzed major immune cell compartments in PBMCs, as well as specific SARS-CoV-2 antibody response in CYP with (n=99) and without (n=18) long COVID at three months following acute infection. Our findings indicate that pediatric long COVID is associated with a dysregulated immune response characterized by altered innate immunity and overactivated T-, B- and NK-cell responses. Furthermore, CYP with long COVID had an impaired humoral response to SARS-CoV-2 marked by a dysregulated B-cell compartment and lower levels of anti-RBD IgG and IgA. This correlated with reduced neutralizing capacity against SARS-CoV-2. Random forest analysis identified CCR6 expression on myeloid cells as the most relevant biomarker that distinguishes long COVID from control individuals with 79% accuracy.

Graphical Abstract
graphical abstract
Supplemental material

View

Version history
  • Version 1 (February 19, 2026): In-Press Preview

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Supplemental material
  • Version history
Advertisement
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts